ROCKVILLE, Md., April 19, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, reiterated that the Exclusive Channel Collaboration Agreement dated August 6, 2012 between the Company and Intrexon Corporation (Intrexon) remains in effect, as stated earlier today. This Exclusive Channel Collaboration Agreement governs a "channel collaboration" arrangement for the use of Intrexon's technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases. About Synthetic Biologics, Inc. Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com. SOURCE Synthetic Biologics, Inc.